@ARTICLE{
author={Goel Shom|,O'Shaughnessy Joyce|,Tan Antoinette R|,Milev-Krastev Boris |,Rugo Hope S|,Aftimos Philippe Georges|,Yardley Denise A|,Andric Zoran G|0000-0002-1495-2729,Wolfgang Curt Douglas|,Sorrentino Jessica|,Tao Wenli|,Beelen Andrew Paul|,Malik Rajesh K|,Jain Sarika|},
year={2021},
title={Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={39},
number={15},
pages={-},
document_type={Meeting Abstract},
}